Skip to main content

VLON

Stock
—
—

Performance overview

VLON Price
Price Chart

Forward-looking statistics

Beta
0.48
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

—

Company info

Sector—
Industry—
Website—
Employees—
Market cap—

Fundamentals

Enterprise value$0.0
Revenue$0.0
Revenue per employee—
Profit margin—
Debt to equity0.00

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)—
Dividend per share—
Revenue per share—
Avg trading volume (30 day)$20M
Avg trading volume (10 day)$1M
Put-call ratio—

Macro factor sensitivity

Growth—
Credit—
Liquidity—
Inflation—
Commodities—
Interest Rates—

Valuation

Dividend yield0.00%
PEG Ratio—
Price to sales—
P/E Ratio2.35
Enterprise Value to Revenue—
Price to book—

Upcoming events

Next earnings dayMay 9, 2022
Next dividend day—
Ex. dividend day—

News

Vallon (VLON) Plummets as ADAIR Study Misses Primary Goal

Vallon Pharmaceuticals (VLON) down as SEAL study evaluating lead investigational product candidate, ADAIR, fails to meet its primary endpoint.

Zacks Investment Research (March 22, 2022)
5 Short Squeeze Candidates To Watch: Petros Pharmaceuticals, iSpecimen Top The List Again

Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next huge movie. GameStop Corp (NYSE:GME) and AMC Entertainment Holdings (NYSE:AMC) are two high-profile examples of short squeezes earlier this year.

Benzinga (December 20, 2021)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free